Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Recruiting in Palo Alto (17 mi)

+23 other locations

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: AbbVie (prior sponsor, Abbott)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.

Eligibility Criteria

Inclusion Criteria

Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview.

Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial Screening Visit; taking same antipsychotic medication(s) for at least 8 weeks prior to the Day -1 visit; core positive symptoms of PANSS no worse than moderate in severity throughout Screening Period of at least 4 weeks.

Has been diagnosed with or treated for schizophrenia for at least 2 years prior to Initial Screening Visit.

See 2 more